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Objectives: Worldwide, women face sexual and reproductive health (SRH) risks including unintended pregnancy and sexually transmitted
infections (STIs) including HIV. Multipurpose prevention technologies (MPTs) combine protection against two or more SRH risks into one
product. Male and female condoms are the only currently available MPT products, but several other forms of MPTs are in development. We
examined the global distribution of selected SRH issues to determine where various risks have the greatest geographical overlap.
Study design: We examined four indicators relevant to MPTs in development: HIV prevalence, herpes simplex virus type 2 prevalence
(HSV-2), human papillomavirus prevalence (HPV) and the proportion of women with unmet need for modern contraception. Using ArcGIS
Desktop, we mapped these indicators individually and in combination on choropleth and graduated symbol maps. We conducted a principal
components analysis to reduce data and enable visual mapping of all four indicators on one graphic to identify overlap.
Results: Our findings document the greatest overlapping risks in Sub-Saharan Africa, and we specify countries in greatest need by specific
MPT indication.
Conclusions: These results can inform strategic planning for MPT introduction, market segmentation and demand generation; data
limitations also highlight the need for improved (non-HIV) STI surveillance globally.
Implications: MPTs are products in development with the potential to empower women to prevent two or more SRH risks. Geographic
analysis of overlapping SRH risks demonstrates particularly high need in Sub-Saharan Africa. This study can help to inform strategic
planning for MPT introduction, market segmentation and demand generation.
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For women, the primary sexual and reproductive health risks
of unprotected sex are unintended pregnancy and a variety of
sexually transmitted infections (STIs), including HIV.Male and
female condoms are the only currently available products that
provide simultaneous protection against these risks, but
acceptability (and cost issues, for female condoms) has
constrained their widespread use [1–2]. A single, safe, effective,
acceptable and accessible product for women that combines
protection frommultiple risks could have significant benefits for
individual and public health.
The emerging field of multipurpose prevention technologies
(MPTs) builds upon previous prevention strategy development
efforts (such as development of HIV-preventive microbicides)
by combining contraception with STI (including HIV)
prevention. According to the World Health Organization
(WHO), eight STIs contribute the greatest burden of disease
attributable to STIs [3]. Four of these STIs are curable
(chlamydia, gonorrhea, syphilis and trichomoniasis); the others
are incurable viral infections, including the following:
(1) HIV in 2013, an estimated 35 million people were
living with HIV, and 2.1 million people were newly
infected. Sub-Saharan Africa remains the most
affected region [4].*  HIV pre
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Fig. 1. HIV prevalence among women aged 1(2) Herpes simplex virus type 2 (HSV-2) causes the
majority of cases of genital herpes. In 2012, 417
million people were living with HSV-2 worldwide,
with women comprising 64% of those infected and
prevalence highest in Africa. Although generally
asymptomatic, HSV-2 is associated with considerable
morbidity and increased risks of HIV acquisition [5].
(3) Hepatitis B virus kills approximately 700,000 people
a year, with prevalence highest in sub-Saharan Africa
and East Asia. Routine inclusion of a vaccine in infant
immunization programs worldwide has already pre-
vented an estimated 1.3 million deaths from chronic
liver disease and cancer [6].
(4) Human papillomavirus (HPV) infection causes more
than 500,000 cases of cervical cancer and 250,000
cervical cancer deaths every year, 85–90% of which
are in low- and middle-income countries. Routine
immunization programs in 45 primarily high-income
countries include the highly effective HPV vaccine.
Thus, a comprehensive approach to HPV prevention
should include vaccination and other measures [7].
In many regions of the world, the impact of HSV-2 and
HPV on population health is of greater concern than that of
HIV due to greater HSV-2 and HPV prevalence relative to
HIV. MPTs that protect against these three viral STIs andvalence among women 15 or older.  Categorization based on epidemic:  low level,
concentrated, generalized epidemic, hyperdemic.
Source: USAIDS, Joint United Nations Programme on HIV/AIDS, 2014.
mitations, where country level data were unreliable, regional estimates were used.
*** Territories were not analyzed.
5 years and older by country or region.
Fig. 2. HSV-2 prevalence among women aged 15–49 years by region.
34 E. Schelar et al. / Contraception 93 (2016) 32–43unintended pregnancy could substantially improve public
health. Thus, we aimed to examine the global distribution of
four MPT targets [HIV, HSV-2, HPV and unmet need for
modern contraception (UNMC)] to document and visualize
where intersecting risks indicate the greatest need forMPTs.We
present a broad, population-level overview of overlapping
burdens that could be ameliorated by access to effective MPTs.1 UNAIDS does not provide country-level estimates for countries
here concern exists about data accuracy, where the total population is less
an 250,000 or where estimates from country teams were not provided [10]
. Mahy, “personal email correspondence,” ed, 2014). These countries
clude Argentina, Austria, Belgium, Bosnia and Herzegovina, Bulgaria,
anada, China, Croatia, Equatorial Guinea, Finland, France, Germany,
reece, Hungary, Iceland, Ireland, Israel, Japan, Kazakhstan, Latvia,
ithuania, Luxembourg, Malta, Mauritania, Montenegro, the Netherlands,
ew Zealand, North Korea, Norway, Oman, the Philippines, Poland,
ortugal, Russia, Singapore, Slovakia, Slovenia, South Korea, Sweden,
urkey and the United States. Values are reported as a range in online
ppendix A. Where no UNAIDS country-level estimate was available,
gional averages were substituted for the following: Antigua and Barbuda,
ahrain, Brunei, Comoros, Dominica, Federated States of Micronesia,
renada, Iraq, Jordan, Kuwait, Lebanon, Libya, Palau, Qatar, Saint Kitts
nd Nevis, Saint Lucia, Saint Vincent and the Grenadines, Samoa, Saudi
rabia, Seychelles, Solomon Islands, Syria, Timor-Leste, Tonga, Turkme-
istan, United Arab Emirates and Vanuatu. Liechtenstein, Monaco and San
arino were not assigned a regional value or a country-level estimate as
ey are not UNAIDS countries included in any estimates.2. Methods
2.1. Indicator selection and categorization
We conducted expert interviews and a literature review to
inform indicator selection, and we obtained prevalence
estimates for each indicator. Since prevalence reflects the
proportion of individuals living with a particular condition, it
does not explicitly capture individuals in need of an MPT for
prevention (i.e., people at risk of acquiring the infection) or with
an interest in using an MPT. However, prevalence is a widely
understood indicator that indicates the degree of health burden.
Availability of data varied by country and indicator and
was limited for HSV-2 and HPV. We used regional data
where country-level data were unavailable. We included
only independent states and excluded Vatican City, Andorra,
Nauru and Tuvalu due to lack of data.We used 2013 Joint United Nations Programme on HIV
and AIDS (UNAIDS) country-level HIV prevalence esti-
mates for women aged 15 years and older [8], calculated
using a standardized estimation methodology across coun-
tries [9]. We derived estimates for certain countries from
unpublished country-level figures provided by UNAIDS1.w
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* HPV prevalence among women 15-19 with normal cytology.
Source:  Bruni, et al., 2015 ICO HPV Information Centre, and Bruni et al., 2010.
**  Due to data limitations, where country level data were unavailable regional estimates were used.
*** Territories were not analyzed.
Fig. 3. HPV prevalence among women aged 15–49 years by country or region.
35E. Schelar et al. / Contraception 93 (2016) 32–43Country-level HSV-2 surveillance varies and is often
incomplete. We obtained prevalence data among women
aged 15–49 years from a review of HSV-2 seroprevalence
studies that calculated pooled prevalence values by age and
sex for each of the six WHO regions2 [5].
Similarly, country-level HPV surveillance varies and is
often incomplete. HPV is a transient infection, unlike HIV
and HSV-2, and prevalence peaks at younger ages, just after
sexual onset, then decreases [11]. For the purpose of this
population-level overview and because subgroup data are
not routinely available, we restricted to women aged 15–
49 years. We obtained country-level estimates from the
Institut Català d’Oncologia (ICO) Information Centre on
HPV and Cancer [12], as well as adjusted regional estimates
from a 2010 meta-analysis3 [13]. We limited estimates to
women with normal cervical cytology to best approximate
prevalence in the general population but inclusive of all HPV
genotypes. HPV prevalence estimates between countries2 Africa, Americas, Eastern Mediterranean, Europe, South-East Asia
and Western Pacific.
3 Middle Africa, Central Asia and Oceania were not available in the
2010 meta-analysis because no data met the quality standards. The Sub-
Saharan Africa regional estimate was used for Middle Africa, and the Asia
regional estimate was used for Central Asia. An Oceania regional estimate
was available from the 2012 update in the ICO HPV Information Centre
database. Only one study was available for the Caribbean regional estimate.may not be comparable due to the use of different HPV
detection techniques, study design and methods and age
distributions within the 15- to 49-year age group; adjusted
regional prevalences can be compared.
UNMC captures the proportion of women aged 15–
49 years who are married or in union, sexually active and
fecund, and who report wanting to stop or delay childbearing
for at least 2 years, but are not using a modern contraceptive
method4 [14]. This indicator intends to measure the gap
between women’s reproductive intentions and their use of
highly effective contraceptive options [15]. We chose this
indicator instead of unintended pregnancy, given greater
country-level data availability and a larger denominator of
sexually active women in union (compared with women with
a recent pregnancy). We also considered using the indicator
“demand for modern contraception,” which would offer insight
into women looking to use contraceptive methods (as some
women with UNMCmay still not use a modern method, even if
available). However, demand would not highlight areas of
particular epidemiological burdens akin to the HIV/STI4 Modern contraceptive methods include female and male sterilization,
ral contraceptive pills, an intrauterine device, male or female condoms,
jectable contraceptives, the contraceptive implant, barrier methods and
mergency contraception, according to the United Nations Department of
ocial and Economic Affairs.o
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*  Unmet need for modern contraception among women aged 15-49.
Source:  UNPD,  United Nations Department of Economic and Social Affairs Population Division, 2014.
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Fig. 4. UNMC among women aged 15–49 years by country.
36 E. Schelar et al. / Contraception 93 (2016) 32–43indicators. We used median estimates from the United Nations’
2012 Population Division annual estimates5 [14,16].
For HIV and HPV, we utilized field standards for data
categorization [17]. WHO and UNAIDS categorize four
epidemiological scenarios for HIV prevalence: low level
(≤1%), concentrated (N1% and ≤5%), generalized (N5%
and ≤15%) and hyperendemic (N15%) [18]. The ICO HPV
Information Centre uses the following categories: b5%, 5–9%,
10–19%, 20–29% and ≥30%. Since UNMC has no standard
categorization scheme, we used Jenks optimization (with
rounded cutpoints), which places cutpoints at natural gaps in
the data distribution [17,19]. We included a separate category
for each of the six WHO regions used for HSV-2 data.2.2. Principal components analysis
To analyze variation among STI/HIV prevalence and
UNMC, we used principal components analysis (PCA), a
data reduction technique commonly used to construct indices
for concepts difficult to quantify with a single metric. This
analysis also enables information on all four indicators to be
displayed on a single map. We conducted PCA calculations5 Several smaller countries do not have data available (see online
Appendix A).using Stata 13.1/SE with all four indicators included as the
variables in the analysis, and we replaced missing data points
using the sample average. We interpret our results as
exploratory due to the limited range of indicators used, the
limited range of variation within the indicators and the
sample size constraints capped by the number of countries
for which data are available. Caveats aside, the application of
PCA on these data can be illustrative for identifying
geographic areas to target MPTs.
2.3. Graphical analysis
We present full numeric data for each indicator by
country in online Appendix A. To facilitate understanding of
the global overlapping risks, we visually represent these data
in global choropleth maps. We used ArcGIS Desktop 10.2.2
[20] with ColorBrewer [21] to create single-layer choropleth
maps for each indicator, a map showing UNMC as graduated
symbols overlaid on the HIV choropleth map, and all other
possible combinations of two indicators (available upon
request). We mapped results of the PCA, which provided the
best possible representation of all four indicators on a single
map. We generated stacked bar graphs to examine the
additive burden of each indicator by country (presented only
for sub-Saharan Africa; others available upon request).
Table 1
Example MPT products in development and corresponding high-burden geographic areas
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Ts
Unmet need for modern contraception
and HIV
Dapivirine plus levonorgestrel
IVR
Biorings TM IVR
Viciviroc (MK4176) + MK2048 +
Progestin IVR
Results presented in Map 5.
Albania, Azerbaijan,
Bosnia & Herzegovina,
Macedonia, Swaziland
(the next 5 are all Sub–
Saharan African Countries)
Based upon ranking the
total summed
prevalence of 2
individual indicators
Comoros, Equatorial Guinea,
Kenya, Malawi, Mozambique,
Tanzania, Uganda, Zambia  
Unmet need for modern
contraception >25%.
HIV prevalence > 5%.
Intended indications for various
multipurpose prevention technology
products (existing [*] or in development)
Top 5 countries with
greatest additive
burden of indicators
Countries simultaneously in top
2 highest categories of indicator
burden
Q
u
ad
ru
pl
e 
in
di
ca
ti
on
 M
P
TS
Unmet need for modern contraception
and HIV and HSV–2 and HPV
MZCL combination topical gel
MZCL combination IVR
Poly–[1,4–phenylene–(1–carboxy) 
methylene] (PPCM) SAMMA gel
Results presented in Map 6, Figure 1, and
Appendix A.
Comoros, Guinea,
Tanzania, Uganda,
Zambia
Based upon ranking the
total summed
prevalence of all 4
individual indicators
Angola, Benin, Bolivia, Burundi,
Cameroon, Central African Republic,
Comoros, Congo (Brazzaville),
Congo (Kinshasa), Equatorial Guinea,
Eritrea, Gabon, Ghana, Haiti,Liberia, Mali,
Mauritania, Samoa, Senegal,Sao Tome
and Principe, Sierra Leone, Somalia,
South Sudan,The Gambia, Togo,
Uganda, Zambia    
Principal component 1 (HIV,
HSV–2, HPV) medium–high or high.
Principal component 2 (unmet
need for modern contraception)
medium–high or high.
Tr
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Unmet need for modern contraception
and HIV and HSV–2
Male condoms*
Female condoms*
90 day tenofovir plus
levonorgestrel IVR
Tenofovir disoproxil fumarate
(TDF) plus levonorgestrel IVR
SILCS diaphragm plus tenofovir
gel 
Results presented on map by request.
Congo (Brazzaville),
Lesotho, Swaziland,
Uganda, Zambia
Based upon ranking the
total summed
prevalence of 3
individual indicators
Comoros, Equatorial Guinea,
Kenya, Malawi, Mozambique,
Tanzania, Uganda, Zambia  
Unmet need for modern
contraception >25%.
HIV prevalence > 5%.
HSV–2 prevalence >18.3%.
HIV and HSV–2 and HPV
Griffithsin gel
Griffithsin plus Zinc acetate in
Carraguard gel
MIV–150 plus Zinc acetate in
Carraguard gel
Results presented in Map 6.
Guinea, Mozambique,
Swaziland, Tanzania,
Zambia
Based upon ranking the
total summed
prevalence of 3
individual indicators
Comoros, Equatorial Guinea,
Kenya, Malawi, Mozambique,
Seychelles, South Africa,
Tanzania, Zimbabwe
HIV prevalence > 5%.
HSV–2 prevalence >18.3%.
HPV prevalence >19%.
(continued on next page)
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D
u
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on
 M
P
Ts
HSV–2 and HPV
Carraguard gel
Results presented on map by request.  
Cote D’ Ivoire, Guinea,
Kenya, Mozambique,
Tanzania, 
Based upon ranking the total
summed prevalence of 2
individual indicators
Angola, Antigua & Barbuda, Barbados,
Burundi, Cameroon, Canada, Central
African Republic, Chad, Comoros,
Congo (Kinshasa), Costa Rica,
Cote D’ Ivoire, Cuba, Dominica,
Dominican Republic, Ecuador,
Equatorial Guinea, Eritrea, Ethiopia,
Gabon, Grenada, Guatemala, Guinea,
Haiti, Honduras, Jamaica, Kenya,
Madagascar, Malawi, Mauritius, Mexico, 
Mozambique, Nigeria, Rwanda,
Saint Kitts & Nevis, Saint Lucia,
Saint Vincent & the Grenadines,
Sao Tome & Principe, South Africa,
South Sudan, Tanzania, The Bahamas,
Trinidad & Tobago, Uganda, Zambia,
Zimbabwe
HSV–2 prevalence >18.3%.
HPV prevalence >19%.
HIV and HSV–2
1.0% Tenofovir gel
Griffithsin Nanofiber Delivery
System
Tenofovir and Acyclovir IVR
Tenofovir and IQP–0528
Tenofovir Disoproxil Fumarate
(TDF) IVR 
Tenofovir IVR
SR–2P Gel
VivaGel
Mapp66 (mAb) film
Tenofovir Alafenamide (TAF) oral
Tenofovir film
Tenofovir vaginal tablet
TFV/FTC vaginal tablet
Results presented on map by request.
Botswana, Lesotho,
South Africa, Swaziland,
Zimbabwe
Based upon ranking the
total summed prevalence
of 2 individual indicators
Angola, Botswana, Comoros,
Equatorial Guinea, Kenya, Lesotho,
Malawi, Mozambique, Namibia, 
Seychelles, South Africa, Swaziland,
Tanzania, Uganda, Zimbabwe
HIV prevalence > 5%.
HSV–2 prevalence >18.3%.
This is not a comprehensive list of all MPTs in development. IVR=intravaginal ring. Italicized products have recently been invested in by United States Agency for
International Development. List includes only products intended to prevent against two or more of the following indications: unintended pregnancy, HIV, HSV-2 or HPV.
Someproducts listedmay have additional expected indications not reflected in this table (e.g., bacterial vaginosis, chlamydia, gonorrhea, etc.). Source for product information:
the Initiative for Multipurpose Prevention Technologies for Reproductive Health MPT database (http://mpts101.org/mpt-database/mpts-topical-gel, accessed 10/18/2014).
aExisting MPT, all other products listed are not yet proven and still in development.
Table 1 (continued)
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3.1. Individual indicators
Southern Africa had the greatest HIV prevalence (among
women aged 15 years and older), followed by Eastern and
Western Africa (Fig. 1). Swaziland had the highest prevalence
(30.1%), followed by Lesotho (24.9%) and Botswana (24.9%).
Africa had the highest HSV-2 prevalence at 38% (Fig. 2).
The other five regions had the following HSV-2 prevalence
estimates: 18.4% in the Americas, 12.6% in the Eastern
Mediterranean, 11.9% in the Western Pacific, 9.8% in Europe
and 8.5% in South-East Asia.
Cervical HPV infection is highly prevalent in adult
women in most of countries. Sub-Saharan Africa, EasternEurope, Latin America and Pacific countries had the highest
levels of HPV (Fig. 3). Western Asia and Southern and
Western Europe had HPV estimates below 10%. Notably,
countries in Southern Africa with particularly high preva-
lence of HIV and HSV-2 had moderate HPV prevalence,
although this could be due to the lack of country-specific
HSV-2 and HPV data; Eastern Africa generally had the
highest HPV prevalence.
Compared to STI prevalence, UNMC varies more within
regions, possibly reflecting the availability of country-level data
and potentially because of diverse drivers for this indicator (e.g.,
contraceptive access, attitudes toward contraceptive use)
(Fig. 4). Eastern Europe, Central Asia and Middle Africa, as
well as the Philippines and Bolivia, had the highest levels of
*  HIV prevalence among women 15 or older.  Categorization based on epidemic: low level,
concentrated, generalized epidemic, hyperendemic.
**  Due to data limitations, where country level data were unavailable regional estimates were used.
Territories were not analyzed.
Source:  UNAIDS, Joint United Nations Programme on HIV/AIDS, 2014.
***  Unmet need for modern contraception among women aged 15-49.
Source:  UNDP, United Nations Department of Social and Economic Affairs Division, 2014.
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Fig. 5. HIV prevalence and UNMC among women.
39E. Schelar et al. / Contraception 93 (2016) 32–43UNMC, while North America, Western Europe, parts of South
America, China and Australia had the lowest.
3.2. HIV and UNMC
Table 1 matches MPT indications to the countries with the
greatest simultaneous burden of these indicators. No country
with the highest prevalence of HIV also ranked in the highest
two levels of UNMC (Fig. 5). Four countries with UNMC
N35% overlapped with the second highest HIV prevalence
category (5–15%): Zambia, Uganda, Equatorial Guinea and
Comoros. Tanzania, Kenya, Mozambique and Malawi ranked
in the second highest category for both HIV and UNMC.
An alternative way of assessing overlap is to examine
additive prevalence. Among all countries, Albania had the
greatest additive HIV prevalence (0.02%) and UNMC (63%),
driven almost exclusively by high UNMC. Other countries
highlighted by this method include Azerbaijan, Bosnia and
Herzegovina, Macedonia and Swaziland (see Table 1).
3.3. Geographical overlap of all four indicators
UNMC correlates weakly with HSV-2 (r=0.2027, pb.01)
and does not correlate with HIV (r=−0.0125) or HPVprevalence (r=−0.0571). HPV is moderately correlated with
HIV (r=0.2068, pb.01) and strongly correlated with HSV-2
(r=0.4716, pb.001). HSV-2 and HIV are most strongly
correlated (r=0.5317, pb.001).
The PCA accounted for the intercorrelation between STIs,
identified two componentswith key information and estimated
the proportion of total variance explained by each. Nearly 50%
of the variance in these data is explained by Component 1
(which generally captures STI variation, including HPV,
HSV-2 and HIV) and over 25% by Component 2 (which
generally captures variation in UNMC). Component 1 has
similar positive factor loadings across the three STIs and a low
loading on UNMC, while Component 2 loads heavily on
UNMC and lightly on the STIs (Appendix B). Some countries
were higher on one component or the other; some were
moderately high on both (see Fig. 6 and Table 1).
Sub-Saharan Africa had the highest values for Component 1,
while Eastern Europe and Central Asia and Middle Africa had
the highest values for Component 2 (Fig. 6). Countries
simultaneously in the top two levels for both Components
include Angola, Benin, Bolivia, Burundi, Cameroon, Central
African Republic, Comoros, Congo (Brazzaville andKinshasa),
Equatorial Guinea, Eritrea, Gabon, the Gambia, Ghana, Haiti,
Fig. 6. HIV, HSV-2, HPV and UNMC among women.
40 E. Schelar et al. / Contraception 93 (2016) 32–43Liberia, Mali, Mauritania, Samoa, Senegal, Sao Tome and
Principe, Somalia, South Sudan, Togo, Uganda and Zambia.
Sub-Saharan Africa was consistently highlighted as a
region of particular need using both PCA and the additive
technique (Table 1; Fig. 7 shows additive prevalence for
Sub-Saharan Africa). Comoros, Guinea, Tanzania, Uganda
and Zambia represent the top five countries with the largest
additive prevalence of all four indicators. However, specific
MPT indications may give rise to different ideal focus
countries (Table 1). For example, while HIV prevalence
alone is greatest in Swaziland, Lesotho and Botswana, an
MPT intravaginal ring (IVR) that combines an antiretroviral
medication (e.g., dapivirine), with a contraceptive hormone
(such as levonorgestrel), could provide significant impact in
Zambia, Uganda and Tanzania where UNMC is also high.6 Appendix C presents a graphical comparison of the country results for
omponent 1 when including the outliers, Albania, Botswana, Lesotho,
amibia, South Africa, Swaziland, Tanzania and Zimbabwe versus
xcluding the outliers to account for the assumption of normal distributions.
he overall pattern of need remains similar. The KMO measure of sampling
dequacy (0.4770) for the full dataset is less robust compared with the
MO for the outlier-excluded dataset (0.6343).4. Discussion
Mapping the burden of viral STIs including HIV and
UNMC is an important step in identifying where MPTs
could offer the greatest impact. This analysis provides the
first examination of regional variation in the overlap of
indications for MPTs globally, documents that the potentialimpact of MPTs is likely greatest in Sub-Saharan Africa and
identifies individual countries where targeted efforts may be
most useful for specific MPT indications.
While a useful step, this analysis occurs within a context
of scarce and imperfect data and with no singular ideal
approach to examining overlapping burdens. Limitations of
PCA include the need to assume normally distributed data;
UNMC met this criterion, but HIV, HSV-2 and HPV
prevalence data skewed toward zero. We conducted a
sensitivity analysis for the PCA, using both the full dataset
and an outlier-adjusted set of data, where outliers falling
more than three standard deviations from the mean value for
each variable were removed; overall, the general pattern
remains the same across both models6. The two ranking
approaches examined generally point to similar focusC
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more countries in Eastern Europe and Central Asia, driven
primarily by UNMC. Since HSV-2 and HPV estimates are
largely regional, reduced variation between countries could
impact additive prevalence ranking results, especially since
the majority of countries in Africa share the same regional
HSV-2 estimate for the entirety of WHO Africa region. The
break points for data categorization impact our examination
of countries simultaneously in the highest categories. For
example, HIV prevalence included only 15 countries in the
top two categories, whereas HSV-2 prevalence included 83
countries in the top two categories.
The clear need for higher-quality, country-level data,
particularly on HSV-2 and HPV, persists. Some estimates
were based on few or older surveys, some pooled estimates
were derived from heterogeneous studies, and except forgeneral inclusion criteria (e.g., use of a type-specific assay
for HSV-2 and adjustment of the HSV-2 prevalence data for
test sensitivity and specificity), studies were not assessed for
quality [5,13,22]. For instance, a single study provided the
high estimate for Tanzania’s HPV prevalence and Southern
African countries have high HPV prevalence but fewer
studies contribute to the 15- to 49-year-old analysis than for
other age groups. A minority of studies used representative
surveys [5,13,22]. We cannot present confidence intervals,
given limitations in data availability.
Furthermore, because prevalencemay vary substantially by
subpopulation, the field needs routinely available, relevant,
disaggregated data to help identify the subpopulations within
countries at greatest need for MPTs. Averages may mask
underlying subgroup variation [9]. Age may be particularly
important, since prevalence of these four indicators
*  Unintended pregnancies per 1,000 women aged 15-49, by subregion, 2012.  Territories were not analyzed.
Data were categorized into the following subregions:  Eastern Africa, Middle Africa, Northern Africa, Southern
Africa, Western Africa, Eastern Asia, South-central Asia, Southeastern Asia, Western Asia, Eastern Europe,
Northern Europe, Southern Europe, Western Europe, Caribbean, Central America, South America, North
America & Oceania.
Source:  Sedgh, Singh, & Hussein, 2014.
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56 - 85 
86 - 108 
No Data 
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Fig. 8. Unintended pregnancy rate per 1000 women aged 15–49 years by subregion.
42 E. Schelar et al. / Contraception 93 (2016) 32–43(particularly HPV, which is transient) varies by age, and age
composition varies between countries. Other sources of
uncertainty include the variability of HPV detection methods
and variation in HPV types among different populations [23].
We used expert input and data availability to guide indicator
selection, and we considered alternate indicators. For example,
UNMC includes a large denominator of women (e.g., not
restricted to currently pregnant women) and country-level
estimates are available, but we also considered subregional
data for unintended pregnancy rates [24]. Comparing Fig. 4
(UNMC) and Fig. 8 suggests a similar regional trend across
Middle Africa, but it highlights some differences: for example,
compared with UNMC, unintended pregnancy rates are
generally higher in Southern Africa, South America and
North America and are lower in Eastern Europe and Central
Asia. As another alternative, contraceptive prevalence rate
could identify locations where specific contraceptive methods
incorporated into MPTs may already be acceptable to women
but may highlight areas where contraceptive use is already
high and the need for additional pregnancy prevention tools is
less urgent. While we have highlighted countries with a high
burden of UNMC or unintended pregnancy rates, countries
with a lower burden may have strong family planningplatforms for programs and policies to build upon and
incorporate the HIV and STI prevention aspects of MPTs,
especially as HIV prevention becomes more widely available.
Including bacterial STIs in future work would help
highlight their potential importance for MPT development,
especially as antibiotic resistance grows [25]. Bacterial STIs
including gonorrhea and chlamydia are highly prevalent and
have long-term negative health effects, such as infertility
[26]. Some bacterial STIs, such as syphilis, have established
surveillance systems and recent data available [27].
While this paper aims to compare worldwide, country-level
overlap of three viral STIs and UNMC, it is important to note
that MPTs may be greatly beneficial and further enhance the
contraceptive mix and STI prevention toolkit even in countries
not highlighted in this analysis. For example, assessing UNMC
would not represent potential MPT users who already use a
modern contraceptive method but would prefer an MPT.
Furthermore, in many of the countries identified as having a
high need for MPTs, gender inequality and sociocultural norms
that limitwomen’s ability to control their own fertility and health
persist. In addition to promoting women’s health, MPTs have
the potential to empower women and girls and yield progress in
other development goals, such as poverty and gender inequality.
43E. Schelar et al. / Contraception 93 (2016) 32–43In sum, understanding which countries bear the greatest
combined burdens of various risks can help to inform
strategic planning for MPT introduction, market segmenta-
tion and demand generation. Our analysis highlights regions
with the greatest epidemiological need according to
designated parameters of selected indicators, while qualita-
tive data can guide development of MPTs that women will
actually use [28]. Both kinds of information will be
necessary for MPTs to reach their greatest potential to
improve women’s lives and global public health.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.contraception.2015.09.002.Acknowledgements
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